Compare VTVT & EML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTVT | EML |
|---|---|---|
| Founded | 2015 | 1858 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.7M | 119.2M |
| IPO Year | 2015 | 1995 |
| Metric | VTVT | EML |
|---|---|---|
| Price | $34.83 | $21.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $53.00 | N/A |
| AVG Volume (30 Days) | ★ 40.9K | 10.3K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 2.00% |
| EPS Growth | N/A | ★ 185.40 |
| EPS | N/A | ★ 1.17 |
| Revenue | N/A | ★ $248,970,345.00 |
| Revenue This Year | N/A | $19.05 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $18.76 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.00 | $17.61 |
| 52 Week High | $44.00 | $26.76 |
| Indicator | VTVT | EML |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 59.64 |
| Support Level | $30.62 | $21.76 |
| Resistance Level | $42.12 | $22.73 |
| Average True Range (ATR) | 2.56 | 0.62 |
| MACD | -0.40 | -0.04 |
| Stochastic Oscillator | 0.69 | 60.19 |
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.